Archives

by in
Entry Author Date Location
Vertex Buys Spine Drug on the QT As Part of Its Post-Hep C Makeover 02/20/15 Boston
WaVe Gets $18M to Solve RNA’s “Underappreciated” Chemistry Problem 02/02/15 Boston
Investors Line up For Westphal as Muscle Cramp Startup Upsizes IPO 01/28/15 Boston
Alnylam CEO: More Cash in Hand Is to Fuel Expansion From Within 01/21/15 Boston
ASH Roundup: Immunotherapy Stars, Gene Therapy Leaps Ahead 12/11/14 San Francisco
After Unlikely Idenix Sale, Renaud Jumps to RaNA to Outfox Junk DNA 12/01/14 Boston
East Coast Biotech Roundup: Agios, Vertex, Epizyme, Celldex, & More 11/21/14 Boston
West Coast Biotech Roundup: Gilead, Juno, Hutch, Fibrogen & More 11/20/14 Seattle
With Atlas Cash and Berkeley Tools, Intellia Joins the CRISPR Fray 11/18/14 Boston
New Research Could (Finally) Remove RNAi’s Commercial Limitations 11/17/14 National
Well-Traveled Rhodes Leaves Epizyme For Atlas Venture Partnership 09/29/14 Boston
East Coast Biotech Roundup: Maraganore, Flex, NPS, Retrophin, & More 09/15/14 Boston
John Maraganore: From “Prototypical Geek” To Canny Alnylam Chief 09/07/14 Boston
BIO 2014: Antisense and Disruptive Technologies for Drug Discovery 06/23/14 San Diego
Lou Tartaglia Leaves Third Rock to Run High-Drama RNAi Startup 06/09/14 San Diego
RNA Therapeutics Are Here to Stay 06/05/14 San Diego
East Coast Biotech Roundup: Neurophage, Boston Biotech, Insmed, & More 03/28/14 Boston
What’s Hot in Boston Biotech: Here’s the Agenda for April 16 03/27/14 Boston
East Coast Biotech Roundup: Dicerna, J&J, Neurophage, & More 01/31/14 Boston
Dicerna Prices Upsized IPO at $15 Per Share, Starts Trading Thursday 01/29/14 Boston
East Coast Biotech Roundup: JP Morgan Edition 01/17/14 Boston
East Coast Biotech Roundup: Scholar Rock, Dicerna, Eleven, & More 01/03/14 Boston
Dicerna Joins Biotech IPO Queue, Plans $69M Raise 01/02/14 Boston
Arrowhead Picks Up Where Roche Left Off, Jumps Ahead in RNAi 12/20/13 Wisconsin
What Was Hyped, and What Fell Out of Favor, This Year in Biotech 12/16/13 National
San Diego Life Sciences Roundup: Illumina, Mirati, Auspex, and More 10/25/13 San Diego
San Diego’s Arcturus Raises $5M for “Best-in-Class” RNAi Technology 10/22/13 San Diego
Profiles in Long-Termism: Sarepta Therapeutics CEO Chris Garabedian 06/10/13 National
Ensysce’s Bet: Combining Two Risky Drug Technologies That Add Up 05/09/13 Texas
AstraZeneca Shells Out $240M Upfront For Moderna mRNA Drugs 03/21/13 Boston
Page 1 of 7 next page »